Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765818744> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2765818744 endingPage "S1569" @default.
- W2765818744 startingPage "S1568" @default.
- W2765818744 abstract "It has been recently observed in lung cancer that certain smoking-related molecular signatures can correlate with a high mutational burden, which may indirectly predict a better clinical response to anti-PD-1 therapy. Based on this, we sought to evaluate the effect of smoking-related clinical/ biochemical characteristics on outcomes in patients while on anti-PD-1 therapy at our institution. We identified a total of 99 patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treated with nivolumab between April 2015 to March 2017 after a first line platinum doublet. Outcomes were assessed mainly in relation to smoking status. Chi-square test and t-test were used to assess correlation among variables. Kaplan Meier method was used to measure survival differences. Median age was 64 years with majority being males (64.6 %). NSCLC was predominant with most common histology being adenocarcinoma in 46% followed by squamous cell (42.5%), the rest being unclassifiable. Most of the patients had quit smoking (67.7%) at the time of anti-PD-1 initiation. The median number of pack years for our cohort was 35. Seven patients in our study were never-smokers. Among smokers vs non-smokers on anti-PD-1 therapy, there was no difference in baseline serum inflammatory biomarkers i.e. c-reactive protein, albumin, neutrophil/lymphocyte ratio. No difference in current smoking status and number of pack-years was seen in patients experiencing grade II-IV immune-related adverse events (38.4%) vs the rest. The mean pack years for adeno vs squamous NSCLC was 52.5 vs 28 (P<0.001). No difference in median overall survival after anti-PD-1 initiation was seen in patients actively smoking vs not smoking while on immunotherapy (6.1 vs 8.5 months; P=0.41). Although some studies have elucidated better response rates in patients based on tobacco exposure, our study demonstrated no differences in serum biomarkers, immune adverse events and overall survival based on smoking status while on anti-PD-1 therapy. This suggests that smoking status may not be a true surrogate of tumor microenvironment and hence not influence survival outcomes." @default.
- W2765818744 created "2017-11-10" @default.
- W2765818744 creator A5048644068 @default.
- W2765818744 creator A5057076335 @default.
- W2765818744 creator A5057970953 @default.
- W2765818744 creator A5067895876 @default.
- W2765818744 creator A5090621600 @default.
- W2765818744 date "2017-11-01" @default.
- W2765818744 modified "2023-09-26" @default.
- W2765818744 title "PS02.12 Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study" @default.
- W2765818744 doi "https://doi.org/10.1016/j.jtho.2017.09.050" @default.
- W2765818744 hasPublicationYear "2017" @default.
- W2765818744 type Work @default.
- W2765818744 sameAs 2765818744 @default.
- W2765818744 citedByCount "0" @default.
- W2765818744 crossrefType "journal-article" @default.
- W2765818744 hasAuthorship W2765818744A5048644068 @default.
- W2765818744 hasAuthorship W2765818744A5057076335 @default.
- W2765818744 hasAuthorship W2765818744A5057970953 @default.
- W2765818744 hasAuthorship W2765818744A5067895876 @default.
- W2765818744 hasAuthorship W2765818744A5090621600 @default.
- W2765818744 hasBestOaLocation W27658187441 @default.
- W2765818744 hasConcept C121608353 @default.
- W2765818744 hasConcept C126322002 @default.
- W2765818744 hasConcept C143998085 @default.
- W2765818744 hasConcept C146357865 @default.
- W2765818744 hasConcept C151730666 @default.
- W2765818744 hasConcept C2776256026 @default.
- W2765818744 hasConcept C2776907518 @default.
- W2765818744 hasConcept C2777701055 @default.
- W2765818744 hasConcept C2780030458 @default.
- W2765818744 hasConcept C2781182431 @default.
- W2765818744 hasConcept C71924100 @default.
- W2765818744 hasConcept C72563966 @default.
- W2765818744 hasConcept C86803240 @default.
- W2765818744 hasConcept C90924648 @default.
- W2765818744 hasConceptScore W2765818744C121608353 @default.
- W2765818744 hasConceptScore W2765818744C126322002 @default.
- W2765818744 hasConceptScore W2765818744C143998085 @default.
- W2765818744 hasConceptScore W2765818744C146357865 @default.
- W2765818744 hasConceptScore W2765818744C151730666 @default.
- W2765818744 hasConceptScore W2765818744C2776256026 @default.
- W2765818744 hasConceptScore W2765818744C2776907518 @default.
- W2765818744 hasConceptScore W2765818744C2777701055 @default.
- W2765818744 hasConceptScore W2765818744C2780030458 @default.
- W2765818744 hasConceptScore W2765818744C2781182431 @default.
- W2765818744 hasConceptScore W2765818744C71924100 @default.
- W2765818744 hasConceptScore W2765818744C72563966 @default.
- W2765818744 hasConceptScore W2765818744C86803240 @default.
- W2765818744 hasConceptScore W2765818744C90924648 @default.
- W2765818744 hasIssue "11" @default.
- W2765818744 hasLocation W27658187441 @default.
- W2765818744 hasOpenAccess W2765818744 @default.
- W2765818744 hasPrimaryLocation W27658187441 @default.
- W2765818744 hasRelatedWork W2388931413 @default.
- W2765818744 hasRelatedWork W2389744545 @default.
- W2765818744 hasRelatedWork W2465910797 @default.
- W2765818744 hasRelatedWork W2544577077 @default.
- W2765818744 hasRelatedWork W2743740828 @default.
- W2765818744 hasRelatedWork W2801241205 @default.
- W2765818744 hasRelatedWork W2898071776 @default.
- W2765818744 hasRelatedWork W2904759734 @default.
- W2765818744 hasRelatedWork W3097428643 @default.
- W2765818744 hasRelatedWork W4200188553 @default.
- W2765818744 hasVolume "12" @default.
- W2765818744 isParatext "false" @default.
- W2765818744 isRetracted "false" @default.
- W2765818744 magId "2765818744" @default.
- W2765818744 workType "article" @default.